NEXT SCIENCE ORD
Next Science Agrees to US$50m Asset Buyout by Italian Healthcare Firm Demetra
Australian medical technology company Next Science (ASX: NXS) has agreed to a US$50 million majority asset buy-out by Italian healthcare collective Demetra Holding SpA. The transaction, which follows a competitive sale process over several months and represents a substantial premium to Next Science’s current market capitalisation, will include the sale of regulatory approvals, contracts, intellectual […]
Market wrap: plenty of underlying action as market moves sideways
At first glance, it appears not much happened on the Australian share market, which managed to eke out a 0.2% gain for the week after a 0.2% retreat on Friday. That is almost the textbook definition of sideways trading but looking further beneath the 17.9 point fall to 7339.5 points on the ASX 200 there […]
Next Science reports potential anti-inflammatory benefits from Xperience in knee study
Medical technology company Next Science (ASX: NXS) has announced the findings of a pilot knee study which used its proprietary Xbio suite of products to reduce the impact of post-operative biofilm-based infections. The double-arm randomised study was led by American orthopaedic surgeon Dr Andrew Wickline using 60 patients who had undergone a total knee arthroplasty. […]
Next Science gears up for ASX debut with product arsenal against antibiotic resistant bacteria
One of this year’s most notable IPOs has been Next Science (ASX: NXS), with the company’s significantly oversubscribed offer closing in just three days – foreshadowing investors’ faith in its already Food and Drug Administration approved Xbio technology for treating chronic infections, including those caused by antibiotic resistant bacteria. As Next Science prepares for its […]
